慢性泪囊炎感染患者的病原菌与药敏分析

Pathogenic bacterial distribution and drug sensitive test results for patients with chronic dacryocystitis

目的分析慢性泪囊炎感染患者病原菌分布及药敏试验结果,为临床合理选择抗菌药物提供依据。方法选取2010年1月-2015年1月医院收治的慢性泪囊炎感染患者156例,分析感染病原菌分布及其耐药率,数据采用SPSS13.0软件进行统计分析。结果 156例慢性泪囊炎感染患者送检标本中98份标本阳性,阳性率为62.82%;共检出病原菌98株,其中革兰阳性球菌72株、革兰阴性杆菌21株、革兰阳性杆菌2株、革兰阴性球菌1株、真菌2株,分别占73.47%、21.43%、2.04%、1.02%和2.04%;革兰阳性球菌主要对万古霉素、庆大霉素、左氧氟沙星和头孢哌酮/舒巴坦最为敏感,敏感率分别为94.44%、90.28%、91.67%和90.28%;革兰阴性杆菌对头孢哌酮/舒巴坦、左氧氟沙星、亚胺培南和美罗培南最为敏感,敏感率分别为95.24%、90.48%、95.24%和90.48%。结论慢性泪囊炎感染患者病原菌以革兰阳性球菌和革兰阴性杆菌为主,由于慢性泪囊炎易反复发作导致病原菌耐药增加,应重视慢性泪囊炎患者的耐药性,为取得更好的临床疗效,应根据药敏试验结果合理选择抗菌药物治疗。

OBJECTIVE To analyze the pathogenic bacterial distribution and drug sensitive test results for patients with chronic dacryocystitis and provide guideline for treatment.METHODS Totally 156 cases of patients with chronic dacryocystitis in our hospital from Jan.2010 to Jan.2015 were selected and the pathogenic bacterial distribution and drug resistance rate were analyzed.RESULTS Among the samples from the 156 patients,98were positive,accounting for 62.82%.Totally 98 pathogenic strains were detected,including 72 strains of gram-positive cocci,21 strains of gram-negative bacilli,2strains of gram-positive rods,1strain of gram-negative cocci and 2strains of fungi,accounting for 73.47%,21.43%,2.04%,1.02%and 2.04%,respectively.Gram-positive cocci were mainly sensitive to vancomycin,gentamicin,levofloxacin and cefoperazone/sulbactam,with sensitive rate as 94.44%,90.28%,91.67%and 90.28%,respectively.Gram-negative bacilli were mainly sensitive to cefoperazone/sulbactam,levofloxacin,imipenem and meropenemm,with sensitive rate as 95.24%,90.48%,95.24%and 90.48%,respectively.CONCLUSIONGram-positive cocci and gram-negative bacilli were the main pathogenic bacteria of chronic dacryocystitis.Due to easy recurrence,the drug-resistance of pathogenic bacteria of chronic dacryocystitis has increased.Clinicians should pay much attention to the resistance and choose antibiotics according to drug sensitive test results in order to achieve better clinical outcomes.